[144] Castle Biosciences, Inc. SEC Filing
Castle Biosciences (CSTL) disclosed a proposed sale of 43,019 common shares through Goldman Sachs & Co. LLC with an aggregate market value of $834,998.79. The form lists the approximate date of sale as 08/13/2025 and identifies the securities exchange as NASD. The shares were recorded as acquired on 08/08/2025 from the issuer as performance award compensation, with payment dated 08/08/2025. The filing also reports multiple related-party sales on 06/27/2025 by The Maetzold trusts and Derek Maetzold totaling specific share amounts and gross proceeds. The filer certifies compliance with Rule 144 and affirms no undisclosed material adverse information.
Castle Biosciences (CSTL) ha reso noto la proposta di vendita di 43,019 azioni ordinarie tramite Goldman Sachs & Co. LLC, per un valore complessivo di $834,998.79. Il modulo indica la data approssimativa di vendita come 08/13/2025 e la borsa come NASD. Le azioni risultano acquisite il 08/08/2025 dall'emittente come compenso sotto forma di premi legati alle prestazioni, con pagamento datato 08/08/2025. La comunicazione riporta inoltre vendite correlate in data 06/27/2025 effettuate dai trust Maetzold e da Derek Maetzold, con quantità di azioni e proventi lordi specificati. Il dichiarante certifica la conformità alla Rule 144 e attesta l'assenza di informazioni materiali non divulgate.
Castle Biosciences (CSTL) divulgó la propuesta de venta de 43,019 acciones ordinarias a través de Goldman Sachs & Co. LLC, por un valor total de $834,998.79. El formulario indica la fecha aproximada de venta como 08/13/2025 y la bolsa como NASD. Las acciones figuran como adquiridas el 08/08/2025 del emisor como compensación en forma de premio por desempeño, con pago fechado el 08/08/2025. La presentación también informa ventas entre partes relacionadas el 06/27/2025 realizadas por los fideicomisos Maetzold y Derek Maetzold, con cantidades de acciones y productos brutos específicos. El declarante certifica el cumplimiento de la Rule 144 y afirma que no existen informaciones adversas materiales no divulgadas.
Castle Biosciences (CSTL)는 Goldman Sachs & Co. LLC를 통해 총액 $834,998.79에 해당하는 43,019 보통주 매각을 제안했다고 공시했습니다. 서류에는 매각의 대략적 예정일을 08/13/2025로 기재하고 거래소를 NASD로 명시했습니다. 해당 주식은 발행사로부터 08/08/2025에 성과 보상(performace award compensation)으로 취득된 것으로 기록되어 있으며 지급일은 08/08/2025입니다. 제출서류는 또한 06/27/2025에 Maetzold 신탁들과 Derek Maetzold가 실시한 관련자 매각 건들을 특정 주식 수량과 총수익과 함께 보고하고 있습니다. 제출인은 Rule 144 준수를 증명하고 공개되지 않은 중대한 불리한 정보가 없음을 확인합니다.
Castle Biosciences (CSTL) a déclaré une proposition de vente de 43,019 actions ordinaires via Goldman Sachs & Co. LLC, pour une valeur totale de $834,998.79. Le formulaire indique la date approximative de la vente au 08/13/2025 et la bourse NASD. Les actions sont enregistrées comme acquises le 08/08/2025 auprès de l'émetteur en tant que rémunération liée à la performance, le paiement étant daté du 08/08/2025. Le dépôt signale également plusieurs ventes entre parties liées le 06/27/2025 par les trusts Maetzold et Derek Maetzold, avec des quantités d'actions et des produits bruts spécifiés. Le déclarant certifie le respect de la Rule 144 et affirme l'absence d'informations matérielles défavorables non divulguées.
Castle Biosciences (CSTL) hat einen geplanten Verkauf von 43,019 Stammaktien über Goldman Sachs & Co. LLC mit einem Gesamtmarktwert von $834,998.79 gemeldet. Das Formular nennt das ungefähre Verkaufsdatum als 08/13/2025 und die Börse als NASD. Die Aktien sind als am 08/08/2025 vom Emittenten als leistungsbezogene Vergütung (performance award compensation) erworben und mit Zahlungsdatum 08/08/2025 verbucht. Die Einreichung berichtet außerdem mehrere Verkäufe zwischen nahestehenden Parteien am 06/27/2025 durch die Maetzold-Trusts und Derek Maetzold mit angegebenen Stückzahlen und Bruttoerlösen. Der Einreicher bescheinigt die Einhaltung von Rule 144 und versichert, dass keine nicht offengelegten wesentlichen negativen Informationen vorliegen.
- Transaction is disclosed via Form 144, indicating compliance with Rule 144 and use of a major broker (Goldman Sachs & Co. LLC)
- Shares to be sold were acquired as performance awards, showing alignment of compensation with equity-based incentives
- Planned sale of 43,019 common shares (aggregate value $834,998.79) could be perceived negatively by some investors monitoring insider selling
- Multiple related-party sales on 06/27/2025 by The Maetzold trusts and Derek Maetzold are disclosed, showing prior liquidation activity by insiders/related parties
Insights
TL;DR: Insiders intend to sell 43,019 performance-award shares via Goldman Sachs; transaction size appears routine versus total outstanding shares.
The planned disposition is of shares recently acquired as performance compensation, routed through a major broker under Rule 144. The filing shows an aggregate market value of $834,998.79 against a reported 29,008,281 shares outstanding, indicating the sale is not a large block relative to total capitalization. Multiple related-party disposals on 06/27/2025 are disclosed, showing prior liquidity events by trusts and an individual. From a market-impact perspective this appears informational and compliant rather than materially dilutive.
TL;DR: The disclosure documents conversion of compensation awards to marketable shares and routine sales by related parties; governance disclosure appears complete.
The form documents that the shares were acquired as performance awards from the issuer and are being offered for sale through an institutional broker, with the filer providing the standard Rule 144 representation about material information. The presence of several trust and individual sales in late June suggests prior planned liquidity by related parties. The filing itself raises no governance red flags but is relevant for stakeholders monitoring insider liquidity and executive compensation monetization.
Castle Biosciences (CSTL) ha reso noto la proposta di vendita di 43,019 azioni ordinarie tramite Goldman Sachs & Co. LLC, per un valore complessivo di $834,998.79. Il modulo indica la data approssimativa di vendita come 08/13/2025 e la borsa come NASD. Le azioni risultano acquisite il 08/08/2025 dall'emittente come compenso sotto forma di premi legati alle prestazioni, con pagamento datato 08/08/2025. La comunicazione riporta inoltre vendite correlate in data 06/27/2025 effettuate dai trust Maetzold e da Derek Maetzold, con quantità di azioni e proventi lordi specificati. Il dichiarante certifica la conformità alla Rule 144 e attesta l'assenza di informazioni materiali non divulgate.
Castle Biosciences (CSTL) divulgó la propuesta de venta de 43,019 acciones ordinarias a través de Goldman Sachs & Co. LLC, por un valor total de $834,998.79. El formulario indica la fecha aproximada de venta como 08/13/2025 y la bolsa como NASD. Las acciones figuran como adquiridas el 08/08/2025 del emisor como compensación en forma de premio por desempeño, con pago fechado el 08/08/2025. La presentación también informa ventas entre partes relacionadas el 06/27/2025 realizadas por los fideicomisos Maetzold y Derek Maetzold, con cantidades de acciones y productos brutos específicos. El declarante certifica el cumplimiento de la Rule 144 y afirma que no existen informaciones adversas materiales no divulgadas.
Castle Biosciences (CSTL)는 Goldman Sachs & Co. LLC를 통해 총액 $834,998.79에 해당하는 43,019 보통주 매각을 제안했다고 공시했습니다. 서류에는 매각의 대략적 예정일을 08/13/2025로 기재하고 거래소를 NASD로 명시했습니다. 해당 주식은 발행사로부터 08/08/2025에 성과 보상(performace award compensation)으로 취득된 것으로 기록되어 있으며 지급일은 08/08/2025입니다. 제출서류는 또한 06/27/2025에 Maetzold 신탁들과 Derek Maetzold가 실시한 관련자 매각 건들을 특정 주식 수량과 총수익과 함께 보고하고 있습니다. 제출인은 Rule 144 준수를 증명하고 공개되지 않은 중대한 불리한 정보가 없음을 확인합니다.
Castle Biosciences (CSTL) a déclaré une proposition de vente de 43,019 actions ordinaires via Goldman Sachs & Co. LLC, pour une valeur totale de $834,998.79. Le formulaire indique la date approximative de la vente au 08/13/2025 et la bourse NASD. Les actions sont enregistrées comme acquises le 08/08/2025 auprès de l'émetteur en tant que rémunération liée à la performance, le paiement étant daté du 08/08/2025. Le dépôt signale également plusieurs ventes entre parties liées le 06/27/2025 par les trusts Maetzold et Derek Maetzold, avec des quantités d'actions et des produits bruts spécifiés. Le déclarant certifie le respect de la Rule 144 et affirme l'absence d'informations matérielles défavorables non divulguées.
Castle Biosciences (CSTL) hat einen geplanten Verkauf von 43,019 Stammaktien über Goldman Sachs & Co. LLC mit einem Gesamtmarktwert von $834,998.79 gemeldet. Das Formular nennt das ungefähre Verkaufsdatum als 08/13/2025 und die Börse als NASD. Die Aktien sind als am 08/08/2025 vom Emittenten als leistungsbezogene Vergütung (performance award compensation) erworben und mit Zahlungsdatum 08/08/2025 verbucht. Die Einreichung berichtet außerdem mehrere Verkäufe zwischen nahestehenden Parteien am 06/27/2025 durch die Maetzold-Trusts und Derek Maetzold mit angegebenen Stückzahlen und Bruttoerlösen. Der Einreicher bescheinigt die Einhaltung von Rule 144 und versichert, dass keine nicht offengelegten wesentlichen negativen Informationen vorliegen.
FAQ
What does the Castle Biosciences (CSTL) Form 144 disclose?
How were the shares acquired that are being sold under the Form 144?
Were there related insider or trust sales recently reported for CSTL?
How many shares outstanding does Castle Biosciences report in the filing?
Which broker and exchange are involved in the planned sale?
